THE ARISING · Clinical Research
A weekly HIV pill passed an important test. Who took it matters.
A phase 3 trial found that, for adults already doing well on a specific daily HIV regimen, switching to once-weekly treatment met the trial’s standard for maintaining viral suppression at 48 weeks.
A treatment schedule shapes a life. Taking a pill every week instead of every day would be a change that some people might welcome. But the first question about a new schedule isn’t whether it sounds easier. It’s what happened when people tried it, and who got the chance to try.
ISLEND-1 enrolled 607 adults across 12 countries. All had HIV-1 that was already suppressed for at least six months while taking the same daily combination of bictegravir, emtricitabine and tenofovir alafenamide. The researchers randomly assigned some of them to switch to weekly islatravir and lenacapavir, while the others continued their daily regimen. Participants and researchers were blinded to who received which active treatment, and participants took matched placebos on the other schedule. So the trial compared the medications under controlled conditions, not what it feels like to take only one pill a week in everyday life.
Why “zero versus one” isn’t the whole result
At week 48, under the study’s rules, none of the 304 participants assigned to weekly treatment and one of the 303 assigned to daily treatment had an HIV RNA level of 50 copies per milliliter or higher. The estimated difference was 0.3 percentage points in favor of the weekly group, with an uncertainty interval that also allowed for a small difference in the other direction. The result met the trial’s prespecified noninferiority standard: the upper end of that interval was below the four-percentage-point margin the study set in advance.
That zero is easy to remember. It is not the same as saying everyone who switched had documented suppression. A result below 50 was documented for 93.4% of the weekly group and 92.4% of the daily group under the trial’s analysis. Serious adverse events occurred in both groups, in 5.3% and 4.6% of participants, respectively. Those counts alone do not tell us that either regimen is safer.
This was a switch study, not a study of starting treatment
ISLEND-1 tested a specific switch in people whose existing medication was already keeping their virus suppressed. It did not test starting treatment in someone with an unsuppressed viral load, or show that a weekly schedule improves adherence in people who have trouble taking a daily pill. It also did not prove the regimens are interchangeable.
What the trial added is narrower and useful: a weekly regimen cleared a prespecified 48-week test in the people studied. If the appeal of a different schedule is that it might fit your life better, that is a good subject to bring to your HIV care team. Don’t change your regimen based on this study.
Source: Rockstroh et al., ISLEND-1 phase 3 randomized trial, The New England Journal of Medicine, October 1, 2026 issue. The study was funded by Gilead Sciences and Merck Sharp & Dohme. This article is based on the published study abstract. General education, not individual medical advice.